NASDAQ: KNSA

Kiniksa Pharmaceuticals International (KNSA) Stock Analysis & Forecast

Nov 13 close

$96.33+0.05 (+0.1%)

Gekko Brief

Nov 9 close

Kiniksa Pharmaceuticals International closed at $98.76 on 9 November 2026, +5.2% on the day. The price sits above both the 50-day ($80.88) and 200-day ($61.79) moving averages, inside a 52-week range of $37.02 to $99.31. The GekkoIndex reads 50, in the Neutral zone, up 4.1 points over five sessions. Gekko Fair Value is $92.05, so the price is 7.3% above it.

The next earnings report is due on 23 February 2027, 100 days away (before open). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 16.8% across the report. Seasonally, the next 20 trading days from this point averaged -0.8% over the last 5 years, rising in 3 of them.

5 firms rate the stock: 5 buy, 0 hold and 0 sell, with a consensus target of $109.43. A typical daily move is about 6.4%, and a typical 20-day move about 7.9%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (fair value).

A plain summary of the figures as of the Nov 9, 2026 close.

Kiniksa Pharmaceuticals International price vs fair value

$96.33$93.08Nov ’25May ’26Nov ’26
Close $96.33200-day averageGekko Fair Value $93.08

Kiniksa Pharmaceuticals International quick facts

Market cap
$7.57B
P/E ratio
72.4
Forward P/E
60.2
EPS, TTM
$1.33
Revenue, TTM
$946.0M
Profit margin
11.6%
Dividend yield
—
Beta
0.08
Volume
464,979 avg 956,487
1-year return
+137.4%
Typical daily move
±6.1%
Typical 20-day move
±8%
50-day average
$82.18
200-day average
$62.83
Next earnings
Feb 23 before open
Shares outstanding
48.84M
52-week range
$37.02$99.31

Kiniksa Pharmaceuticals International swing-trade checklist

Kiniksa Pharmaceuticals International scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive3 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $96.33 is above the 50-day ($82.18) and 200-day ($62.83) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    52.5, Neutral

    Reading 52.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    3.5% above

    Price is within 5% of Gekko Fair Value (3.5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    −0.2% on average

    From this point in the calendar, the next 20 trading days averaged −0.2% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Kiniksa Pharmaceuticals International stock chart and price history

Kiniksa Pharmaceuticals International closed at $96.33 on Nov 13, 2026, +137.4% over the past year, inside a 52-week range of $37.02 to $99.31.

Close50-day average200-day averageVolume
Kiniksa Pharmaceuticals International share price, past year, with 50-day and 200-day moving averages and volume$40$60$80DecJan 2026FebMarAprMayJunJulAugSepOctNov96.33

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+20.5%
3 months
+21.7%
6 months
+70.5%
1 year
+137.4%
The full KNSA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KNSA in Gekko

Follow Kiniksa Pharmaceuticals International through every session

Put KNSA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track KNSA in GekkoFree for 7 days. No credit card required.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International develops and sells medical treatments, working across the United States, the United Kingdom, and other countries. Its established product is ARCALYST, a cytokine-trapping therapy that targets interleukin-1alpha and 1beta and is used to treat recurrent pericarditis, an inflammatory heart condition, as well as cardiac sarcoidosis.

Beyond its marketed therapy, the company is advancing a pipeline of antibody-based candidates. KPL-387, a fully human monoclonal antibody, is being studied in a combined Phase 2/3 trial for recurrent pericarditis, while KPL-116, an Fc-modified monoclonal antibody, remains in earlier pre-clinical development. The company was previously called Kiniksa Pharmaceuticals, Ltd. before adopting its current name in June 2024.

Founded in 2015, Kiniksa Pharmaceuticals International is headquartered in London, United Kingdom. Its shares trade on the NASDAQ under the ticker KNSA.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
kiniksa.com

Kiniksa Pharmaceuticals International GekkoIndex: the smart money zone

Kiniksa Pharmaceuticals International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.5, in the Neutral zone, up 1.6 points over five sessions.

010052.5Neutral

Up 1.6 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying27+3.5%+7.7%+14.3%+15.1%
Accumulation149+2.6%+4.9%+8.3%+13.6%
Neutral (current zone)464+1.0%+2.1%+4.1%+12.9%
Distribution58+0.2%−0.1%+1.5%+9.0%
Selling4Too few readings yet

Average KNSA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the KNSA price, zone by zone.Track KNSA in Gekko

Is Kiniksa Pharmaceuticals International stock overvalued? Gekko Fair Value

Kiniksa Pharmaceuticals International trades 3.5% above Gekko Fair Value of $93.08, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Kiniksa Pharmaceuticals International shares are worth, recalculated every trading day.

$93.08

Gekko Fair Value, Nov 14, 2026

3.5% above fair value · About fair value

At the end of Aug 2026 the price was 10.9% below the estimate.

Gekko Fair ValueShare price, month end
$93$96Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open KNSA in Gekko

Kiniksa Pharmaceuticals International insider and Congress trading

No open-market insider purchases were filed for Kiniksa Pharmaceuticals International, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for KNSA in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every KNSA insider filing, plotted on the chart in Gekko.Open KNSA in Gekko

Congress trades last 90 days

No trades in KNSA were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for KNSA, plotted on the chart in Gekko.Open KNSA in Gekko

Buybacks

Kiniksa Pharmaceuticals International has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$316K
As a share of market cap
0.00%
Trailing four quarters
$5.90M

From company filings.

Kiniksa Pharmaceuticals International earnings: next date and track record

Kiniksa Pharmaceuticals International reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±16.8%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

+0.3%Feb ’25+25.6%Apr ’25+11.2%Jul ’25−7.9%Oct ’25−9.8%Feb ’26+21.5%Apr ’26+27.4%Jul ’26+30.4%Oct ’26

Last earnings call, Oct 27, 2026 AI summary

What they said
Kiniksa reported Q3 2026 ARCALYST revenue of $286M, with full-year guidance raised to $1.045-$1.050B, marking blockbuster status. Penetration into the 14,000 annual multiple-recurrence patients reached 23%. Pipeline assets KPL-387 (Phase III) and KPL-1161 (entering Phase I) are advancing, with KPL-387 data expected in H2 2027 and potential launch in 2028-2029.
Guidance
Full-year 2026 revenue guidance raised to $1.045-$1.050B. KPL-387 Phase III data expected H2 2027, with commercial launch targeted for 2028-2029. KPL-1161 Phase I trial expected to initiate by year-end 2026.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 27, 2026$0.56
est $0.37
+50.9%$286.0M
est $260.7M
+9.7%+30.4%
Jul 28, 2026$0.30
est $0.30
+0.2%$243.6M
est $226.5M
+7.6%+27.4%
Apr 28, 2026$0.27
est $0.18
+50.0%$214.3M
est $206.1M
+4.0%+21.5%
Feb 24, 2026$0.17
est $0.29
−41.4%$202.1M
est $200.8M
+0.7%−9.8%
Oct 28, 2025$0.23
est $0.32
−27.4%$180.9M
est $197.1M
−8.2%−7.9%
Jul 29, 2025$0.23
est $0.18
+27.8%$156.8M
est $166.5M
−5.8%+11.2%
Apr 29, 2025$0.11
est $0.02
+450.0%$137.8M
est $131.9M
+4.5%+25.6%
Feb 25, 2025−$0.12
est $0.02
−700.0%$122.5M
est $123.4M
−0.7%+0.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Kiniksa Pharmaceuticals International stock forecast and analyst price targets

Analysts’ average 12-month price target for Kiniksa Pharmaceuticals International is $109.43, +13.6% from the last close, from 5 firms rating the stock in the last 90 days.

$109.43consensus 12-month target, +13.6% from the last close
Low $98High $122
Buy5
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 5 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 30J.P. MorganBuy, reiterated$122+26.6%
Oct 28Wells FargoBuy, maintained$110+14.2%
Oct 28Canaccord GenuityBuy, maintained$98+1.7%
Oct 27Goldman SachsBuy, reiterated$101+4.8%
Oct 23Canaccord GenuityBuy, reiterated$98+1.7%
+4.1%average 20-day move after past Neutral readings
−0.2%average move over the next 20 trading days in the last 5 years
±6.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Kiniksa Pharmaceuticals International seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Kiniksa Pharmaceuticals International averaged −0.2% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−4.9%2021+1.7%2022+10.1%2023−7.4%2024+3.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.5%2 of 5
Next 10 trading days−1.6%2 of 5
Next 15 trading days+0.9%3 of 5
Next 20 trading days−0.2%3 of 5
Next 30 trading days−1.9%2 of 5

For scale, KNSA’s typical 20-trading-day move in either direction is about 8%.

Kiniksa Pharmaceuticals International market cap and key statistics

Kiniksa Pharmaceuticals International’s market cap is $7.57B, with a P/E ratio of 72.4 and revenue of $946.0M over the last twelve months.

Valuation

Market cap
$7.57B
P/E ratio
72.4
Forward P/E
60.2
EPS, TTM
$1.33
Gekko Fair Value
$93.08

Trading

Volume
464,979
Avg volume, 20 days
956,487
52-week high
$99.31
52-week low
$37.02
Shares outstanding
48.84M

Financials

Revenue, TTM
$946.0M
Profit margin
11.6%
Return on equity
17.6%
Quarterly earnings growth, YoY
+143.5%

Risk and income

Beta
0.08
Typical daily move
±6.1%
Typical 20-day move
±8%

Kiniksa Pharmaceuticals International stock news this week

Coverage of Kiniksa Pharmaceuticals International this week reads negative: 0 positive, 1 neutral and 2 negative headlines.

News sentiment negative

Kiniksa Pharmaceuticals International peers

Kiniksa Pharmaceuticals International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Kiniksa Pharmaceuticals International stock FAQ

What is Kiniksa Pharmaceuticals International’s market cap?

Kiniksa Pharmaceuticals International’s market cap is $7.57B at the Nov 13, 2026 close of $96.33, with 48.84M shares outstanding. The shares trade on a P/E ratio of 72.4.

What is the Kiniksa Pharmaceuticals International stock forecast?

The consensus analyst 12-month price target for Kiniksa Pharmaceuticals International is $109.43, +13.6% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Kiniksa Pharmaceuticals International stock overvalued or undervalued?

On Gekko’s estimate Kiniksa Pharmaceuticals International is about fair value: the Nov 13, 2026 close of $96.33 is 3.5% above Gekko Fair Value of $93.08. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Kiniksa Pharmaceuticals International report earnings next?

Kiniksa Pharmaceuticals International is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.25 per share on revenue of $306.6M. Kiniksa Pharmaceuticals International beat the earnings estimate in 5 of its last 8 reports, moving 16.8% on average across the report.

What is Kiniksa Pharmaceuticals International’s 52-week high and low?

Kiniksa Pharmaceuticals International’s 52-week high is $99.31 and its 52-week low is $37.02; it closed at $96.33 on Nov 13, 2026, +137.4% over the past year.

Is Kiniksa Pharmaceuticals International stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Kiniksa Pharmaceuticals International the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.